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Background: Glioblastoma multiforme (GBM) is the most common primary central nervous system neoplasm in
adults. Radioactive 125I seed implantation has been widely applied in the treatment of cancers. Moreover, previous
clinical trials have confirmed that 125I seeds treatment was an effective therapy in GBM. We sought to investigate
the effect of 125I seed on GBM cell growth and Epithelial-mesenchymal transition (EMT).
Methods: Cells were exposed to irradiation at different doses. Colony-formation assay, EdU assay, cell cycle analysis,
and TUNEL assay were preformed to investigate the radiation sensitivity. The effects of 125I seeds irradiation on EMT
were measured by transwell, Boyden and wound-healing assays. The levels of reactive oxygen species (ROS) were
measured by DCF-DA assay. Moreover, the radiation sensitivity and EMT were investigated with or without pretreatment
with glutathione. Additionally, nude mice with tumors were measured after treated with radiation.
Results: Radioactive 125I seeds are more effective than X-ray irradiation in inhibiting GBM cell growth. Moreover, EMT
was effectively inhibited by 125I seed irradiation. A mechanism study indicated that GBM cell growth and EMT inhibition
were induced by 125I seeds with the involvement of a ROS-mediated signaling pathway.
Conclusions: Radioactive 125I seeds exhibit novel anticancer activity via a ROS-mediated signaling pathway. These
findings have clinical implications for the treatment of patients with GBM by 125I seeds.
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Glioblastoma multiforme (GBM) is the most common
and lethal type of primary central nervous system
neoplasm in adults [1]. Unlike most other tumors
that metastasize to distant organs, malignant glioma
very rarely metastasizes outside the central nervous
system. In this sense, GBM may be regarded as a
“local” tumor [2]. In GBM, standard treatment involves
maximal resection followed by concomitant and adjuvant
chemoradiotherapy with temozolomide. Even with this* Correspondence: yao.kaitai@yahoo.cn
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unless otherwise stated.comprehensive treatment strategy, outcomes for patients
with this malignancy remain very poor. Thus, in order to
improve the current therapeutic regimens, it is important
to explore effective new modalities for GBM patients.
Radioactive 125I seed implantation has been widely applied
in the treatment of cancers [3-6]. It has been shown to be
an effective adjuvant therapy in recurrent GBM [7,8] and
Low-grade (WHO grades I and II) gliomas (LGGs) [9,10].
Furthermore, several studies have shown that 125I seed
irradiation directly causes more cell death by comparing
with 60CO-γ or X-ray irradiation [11-14]. However, few
studies of the biological effects of 125I seed irradiation on
GBM cells are available.
Epithelial–mesenchymal transition (EMT) is a key
developmental program that is often activated duringis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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gone EMT are resistant to many of the chemotherapeutic
and adjuvant drugs that are used to treat epithelial tumors,
and may therefore drive tumor recurrence [16,17]. For the
lack of E-cadherin expression in GBM cells suggesting a
non-classic EMT, only very few recent reports described
an EMT phenomenon in GBMs and its association with
the poor prognostic mesenchymal subgroup of GBMs [18].
Reactive oxygen species (ROS) play an important role in
cellular metabolism and cancer therapy [19,20]. The
absorption of ionizing radiation by living cells can act
indirectly through radiolysis of water, thereby generating
ROS [21]. Moreover, in the past few years, nuclear
DNA damage-sensing mechanisms activated by ionizing
radiation have been identified, including ataxia-telangiectasia
mutated (ATM)/ATM-and Rad3-related (ATR) and the
DNA-dependent protein kinase [22,23].
Therefore, in this study, we evaluated the effect of
radioactive 125I seeds on GBM cell growth and EMT. The
results showed that radioactive 125I seeds were more effect-
ive than X-ray irradiation in inhibiting GBM cell growth.
Moreover, EMT in GBM cells was effectively inhibited
by 125I seed irradiation. A mechanism study indicated that
GBM cell growth and EMT were inhibited by 125I seeds
with the involvement of a ROS-mediated signaling pathway.
Pretreatment of cells with glutathione (GSH) significantly
blocked 125I seed irradiation-induced inhibition of cell
migration and growth by recovering the expression levels
of ROS. Meanwhile, the results of an in vivo study con-
firmed that 125I seed irradiation inhibits tumor growth
and EMT via a ROS-mediated signaling pathway. Taken
together, these results suggest that radioactive 125I seeds
exhibit novel anticancer activity via a ROS-mediated sig-
naling pathway. These findings have clinical implications
for the treatment of patients with GBM by 125I seeds.
Methods
Cell culture and reagents
U251 and U87 human GBM cell lines were available at
the Cancer Institute of Southern Medical University
(Guangzhou, China) and were originally purchased from
the American Type Culture Collection (ATCC). Cells
were maintained in Dulbecco’s Modified of Eagle Medium
(DMEM) supplemented with 10% fetal bovine serum
(FBS) and antibiotics (100 IU/ml penicillin and 100 mg/ml
streptomycin) at 37°C under a humidified atmosphere of
95% air and 5% CO2. To investigate the effect of ROS on
migration, 5 mM GSH (Sigma-Aldrich, MO, USA) was
added 2 hours before irradiation.
Treatment of GBM cells with 125I seeds and X-ray
irradiation
125I seeds were obtained from Beijing Atom and High
Technique Industries Inc. (Beijing, China). The in vitroirradiation was carried out as previously described [13].
The absorbed doses were calculated as follows: 44, 92,
144, and 204 hours were required for doses of 2, 4, 6, and
8 Gy, respectively [14]. X-ray irradiation with a clinically
calibrated irradiation field of 10 × 10 cm was performed at
the Department of Radiotherapy, Armed Police Corps
Hospital of Guangdong Province, using the Elekta precise
treatment system (Stockholm, Sweden).
Colony-formation and thiazolyl blue tetrazolium bromide
(MTT) assay
According to a previous study, the plating efficiency (PE)
of unirradiated controls was calculated using the following
formula: number of colonies/number of seeded cells ×
100%. U87 and U251 cells were exposed to radiation and
then seeded using a cell-dilution assay. Surviving fractions
(SFs) were calculated as following formula: SF = number of
colonies/number of seeded cells × PE. The dose–survival
curve was fitted based on the single-hit multi-target theory
formula: SF =1 - (1 - eD/D0) N; logN=Dq/D0. Cell viability
was determined by MTTassay as previously described [24].
Annexin V-PI apoptosis and Caspase-3 activity assay
Cells in exponential growth were irradiated and harvested
24 hours after irradiation. Then cells were assessed
according to the protocol of the Alexa Fluor® 488 annexin
V/Dead Cell Apoptosis kit (Invitrogen, CA, USA). For
caspase-3 activity, cells incubated 48 hours after irradiation
at different doses were lysed with lysis buffer (100 μl per
2 × 106 cells) for 15 minutes on ice following washing with
D-Hank’s medium. Then cell extracts mixed with
Ac-DEVD-pNA substrate were incubated at 37°C for
2 hours. The values measured by colorimetric measure-
ment of p-nitroanilide product at 405 nm were normalized
to untreated controls allowing determination of the fold
change in caspase-3 activity.
Cell cycle measured by flow cytometry
Cells in exponential growth were irradiated and harvested
24 hours after irradiation. Then they were washed with
cold phosphate-buffered saline (PBS) and fixed overnight
in cold 70% ethanol. Fixed cells washed with PBS were
resuspended in 100 μl RNaseA (250 μg/ml), incubated
for 30 minutes at 37°C. Then, 50 μg/ml PI was added
and incubated at room temperature in the dark for
30 minutes followed by PI-detection with BD FACSCAria™
(BD Biosciences, CA, USA).
Analysis of apoptosis by terminal deoxynucleotidyl
transferase (TdT)-mediated dUTP-digoxigenin nick-end
labeling (TUNEL) assay
We applied a TUNEL assay according to the manufac-
turer’s instructions (Beyotime Institute of Biotechnology,
Jiangsu, China) to evaluate the apoptotic response in
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were fixed with 3.7% formaldehyde and permeabilized
with 0.1% Triton X-100 in PBS. Then, the cells were
incubated with TUNEL reaction mixture for 1 hour and
cell nuclei were stained with 4′, 6-diamino-2-phenylindole
(DAPI; Invitrogen). The cells were then washed with PBS
and examined.
Transwell and Boyden chamber assays
Cells (106 cells/100 μl) in serum-free DMEM were added
to the upper chamber and 500 μl of the DMEM with
10% FBS was added to the lower chamber with permeable
supports (Corning, NY, USA). Then, cells on the upper
surface which were incubated for 24 hours at 37°C were
removed using a cotton-tipped applicator. Finally,
cells on the lower surface of the filter were stained
with crystal violet to calculate the average number of
migrated cells [25].
Wound-healing assay
Cells exposed to irradiation at a dose of 4 Gy were
scraped with a conventional 10 μl micropipette tip
across the monolayer. The distance between the wound
edges was measured immediately and again 24 hours
later. The total distance migrated by wounded U251
and U87 cells was evaluated using Adobe Photoshop
and is expressed as a percentage of the initial wound
distance.
Immunofluorescence assay
Cells seeded on slides were fixed in 4% paraformaldehyde
and permeabilized in 0.5% Triton X-100. Primary antibody
(1:200; Santa Cruz Biotechnology, CA, USA) and Alexa
Fluor 488-conguated secondary antibody (1:500; Invitrogen)
were used to detect the location and expression of
E-cadherin and vimentin. The cell nuclei were stained with
DAPI. Finally, the images were recorded by fluorescence
microscopy with a Nikon eclipse 80i microscope.
Detection of ROS in intracellular
For intracellular ROS analysis, cells were loaded with
10 μM DCF-DA (Sigma-Aldrich), incubated at 37°C for
30 minutes, and immediately analyzed by microscope
and flow cytometry (BD Biosciences).
Western blotting analysis
Cells and tissues were lysed in RIPA buffer. Tumors were
ground in liquid nitrogen and lysed. Protein concentration
was determined using the BCA Kit (Beyotime Institute of
Biotechnology). Proteins were mixed with loading buffer
and heated at 70°C for 10 minutes on sodium dodecyl
sulfate (SDS)-polyacrylamide gels at 30 μg per lane. The
proteins were transferred to polyvinylidene fluoride (PVDF,
Millipore, MA, USA) after electrophoresis. Membraneswere blocked for 2 hours in 5% BSA and incubated over-
night at 4°C with antibodies against γ-H2AX, ATM, ATR,
Chk1, cell-cycle controller-2 (Cdc2), E-cadherin, vimentin,
caspase-3, and caveolin-1 (Cav-1). The blots were then in-
cubated with HRP-conjugated secondary antibody (1:1000;
Santa Cruz Biotechnology). Finally, bands were visual-
ized by enhanced chemiluminescence (Thermo Scientific
Pierce, IL, USA).
In vivo experiments
Female BALB/c nude mice (age 4–5 weeks) were
purchased from the Model Animal Research Center
of Nanjing University (Nanjing, China). This study
was approved by the ethics committee of Southern
Medical University. Animals were injected subcutaneously
(s.c.) with U251 cells into the right hind limb (5 × 106 cells/
100 μl). Two weeks later, mice whose tumor volumes had
reached approximately 200 mm3 were randomly divided
into three groups with 4 mice in every group. The three
groups were: (1) irradiation at 20 Gy (2 Gy/day × 10 F, 5
fractions/week for X-ray irradiation); (2) implanted
with 125I seeds at a total dose of 20 Gy, the number
of which calculated by the treatment planning system (TPS)
(RT-RSI, Beijing Atom and High Technique Industries Inc.,
Beijing, China); and (3) untreated group. The dimensions of
xenograft nodules were callipered every 3 days for 2
successive weeks. The animals were euthanized day
15 after treatment. Finally, immunohistochemistry (IHC)
and western blotting for E-cadherin and vimentin were
performed in xenograft tumor samples.
Statistical analysis
Statistical analysis was performed with the SPSS statistical
package (v15.0). In vitro experiments were usually
performed in triplicate and repeated three times. The
data are presented as mean ± standard deviation (SD).
Statistical differences among groups were examined using
one-way analysis of variance (ANOVA), with p values of
less than 0.05 considered statistically significant. Multiple
comparisons of the means were done by the least signifi-
cance difference (LSD) test.
Results
Radioactive 125I seeds are more effective than X-ray in
inhibiting GBM cell growth
In this study, the effects of irradiation on the growth of
GBM cells were measured by colony-formation, MTT,
and apoptosis assay. The results showed that the
colony-formation ability was significantly reduced by
irradiation in a dose-dependent manner (Figure 1A).
The SFs of cells exposed to 125I seed irradiation were
significantly lower than that of cells exposed to X-ray
irradiation at the same doses, both in U251 and U87
cells. Based on the dose-survival curve fitted with the
Figure 1 Glioblastoma multiforme (GBM) cells are more radiosensitive to 125I seed irradiation than X-ray. (A) Representative pictures of
the colony-formation ability of U251 (upper panel) and U87 (lower panel) cells exposed to 125I seed and X-ray at various doses for 14 days. The
survival fraction of the colony-formation assay was fitted by the single-hit multi-target theory formula. (B) The cell viability of U251 (left panel) and
U87 (right panel) cells treated with irradiation was examined by MTT assay. (C) Proliferation of U251 (upper panel) and U87 (lower panel) cells was
measured by EdU assay. Significant differences between the 125I seed and X-ray groups under the same dose are indicated by *P <0.05 and **P < 0.01.
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of 125I seeds and X-ray were 1.703 versus 0.722 and
19.245 versus 5.736 in U87. Moreover, the MTT assay
also confirmed that the viability of cells exposed to
125I seeds was lower than that of cells exposed to X-ray
irradiation (Figure 1B), especially at a dose of 4 Gy; the
SF decreased from 77.63% to 47.57% in U251 cellsand from 84.42% to 61.69% in U87 cells. Finally, cell
proliferation was measured and the results indicated
that the cell proliferation of U251 and U87 was sig-
nificantly inhibited by irradiation in a dose-dependent
manner. However, compared with the X-ray group,
the cell proliferation was significantly inhibited by 125I
seeds at the same doses (Figure 1C). Taken together, these
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seed irradiation than to X-ray irradiation.
An annexin V– PI apoptosis assay was performed to
examine the effect of 125I seed irradiation on cell death.
The results showed that apoptotic cell death was markedly
induced by X-ray and 125I seed irradiation in a dose-
dependent manner. After X-ray irradiation, apoptosis
significantly increased in GBM cells. However, compared
with X-ray irradiation, 125I seed irradiation led to a higher
percentage of apoptosis under the same doses. For
example, the apoptotic rate after 125I seed irradiation at
a dose of 4 Gy increased from 2.12% (control) to
15.21% in U251 cells and to 14.26% in U87 cells
(Figure 2A and B). We further investigated whetherFigure 2 Apoptosis and G2/M arrest in glioblastoma multiforme (GBM
cells was examined by Annexin V-PI co-staining flow cytometric analysis (A
cell-cycle distribution of GBM cells were examined by flow cytometric anal
U251 (left panel) and U87 (right panel) cells. (F) Treatment of cells with 125
accompanied by up-regulation of cleaved caspase-3, cleaved PARP, and ph
Significant differences between the 125I seed and X-ray groups under the sthe observed irradiation-induced apoptosis was related to
caspase-3. As expected, the results showed that caspase-3
activity increased after irradiation, with 125I seed irradiation
exhibiting a greater effect on caspase-3 activity compared
with X-ray (Figure 2C). To gain a better understanding of
the apoptosis induced by the ionizing irradiation, DNA
distribution histograms of GBM cells were acquired. The
results indicated that dose-dependent increases in the
G2/M cell population were observed in cells exposed
to X-ray and 125I seed irradiation, without significant
differences in the S and G0/G1 phases (Figure 2D).
As we know, TUNEL-positive cells showed typical
apoptosis. The results of our study indicate that the
number of TUNEL-positive cells was significantly) cells is induced by 125I seed irradiation. Apoptosis of GBM
, B) and caspase-3 activity assay (C). (D) Effects of 125I seed on the
ysis. (E) TUNEL assay was used to evaluate the apoptotic response in
I seeds caused obvious apoptosis in a dose-dependent manner,
osphorylated Cdc2 (Tyr 15). Data are presented as mean ± SD (n =3).
ame dose are indicated by *P <0.05 and **P < 0.01.
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X-ray irradiation at the same doses (Figure 2E). With
irradiation at a dose of 4 Gy, the percentage of apoptotic
cells increased to 19.18% with 125I seed treatment,
compared with 12.32% with X-ray. The enzyme poly-
ADP-ribosepolymerase (PARP), the expression of which is
triggered by DNA-strand breaks, acts as a substrate for
caspases. In cells undergoing apoptosis, it is cleaved by
caspase-3 during the degradation of cellular DNA, thus
preventing DNA damage repair. It is therefore critical
for the repair of some DNA lesions [26,27]. Historically,
mitotic entry and exit were thought to be a direct conse-
quence of Cdc2 activation and inactivation, respectively
[28]. Therefore, PARP, caspase-3, and Cdc2 in U251 were
measured by western blotting to further confirm the
apoptosis and G2/M arrest induced by 125I seeds. As
expected, treatment of cells with 125I seeds caused obvious
apoptosis and G2/M arrest in a dose-dependent manner,
as accompanied by up-regulation of cleaved caspase-3,
cleaved PARP, and phosphorylated Cdc2 (Tyr 15).
Interestingly, results indicated that O6-methylguanine
DNA methyltransferase (MGMT) which was an inde-
pendent favorable prognostic factor in patients with
GBM [29] was also up-regulated by irradiation (Figure 2F).
Altogether, these results suggest a higher potency of
125I seed irradiation in inducing cancer-cell apoptosis
and G2/M arrest.
Effects of irradiation on EMT in GBM cells
GBM cells are characterized by migration and invasion
into the surrounding normal brain tissue. This study
compared the EMT in GBM cells with X-ray and 125I seed
irradiation. As shown in Figure 3A, transwell and Boyden
chamber assays were performed to investigate the effects
of these treatments on cell invasion and migration. After
X-ray irradiation, the number of migrating cells per
high-power field (HPF) in U251 cells increased from
42.3 to 59.4, whereas it reduced to 22.9 after 125I seed
irradiation. Similar findings were seen with U87 cells: the
number of migrating U87 cells decreased significantly
after 125I seed irradiation. When the potential involvement
of 125I seeds in reducing the invasion of GBM cells was
determined by Boyden chamber assay, there was a
two-fold decrease in the number of invading cells of
both U251 and U87 compared with the control
group. As shown in Figure 3B, the migration index of
125I seed irradiation measured by wound-healing assay
reduced from 40.9% to 22.1% compared with control.
However, a higher migration index of U251 cells was
observed 24 hours after X-ray irradiation. Moreover,
dramatic morphological changes, in which the spindle-
like, fibroblastic morphology was replaced by a typical
cobblestone-like appearance of normal epithelium,
indicating inhibition of EMT by 125I seeds, were observedin 125I seed-treated GBM cells (Figure 3C). In GBM cell
lines, the capabilities of motility and invasion have been
ascribed to Snail and ZEB1 expression [30]. Thus, our
studies investigated the levels of ZEB1 and Snail. Our
results indicated that the levels of ZEB1 were involved in
EMT inhibited by 125I seeds, with no significant changes
in Snail in U251 and U87. As anticipated, decreased
vimentin were also observed in 125I seed-treated U87 and
U251 cells (Figure 3D). To further test the hypothesis that
125I seeds inhibit EMT, the results of immunofluorescence
assay indicated that 125I seeds down-regulated ZEB1 in
the nuclear of U251 cells, suggesting that 125I seeds inhibit
EMT in GBM cells (Figure 3E). Taken together, these
results demonstrate that 125I seed irradiation inhibits the
nonclassic EMT in GBM cells.
Radioactive 125I seeds suppress cell migration and growth
via a ROS-mediated signaling pathway
Studies have shown that ROS play an important role in
cancer therapy; in particular, low- linear energy transfer
(LET) radiation exposure is more dependent on ROS
generation. Therefore, we hypothesized that 125I seeds
may inhibit cell growth and EMT via increased ROS
generation in GBM cells. To test this hypothesis, we
sought to determine whether 125I seeds were more
effective than X-ray in generating ROS. DCF-DA
staining and flow cytometric assays showed that the
levels of ROS were markedly increased in U251 and
U87 cells after 24 hours of 125I seed irradiation. As shown
in Figure 4A, the degree of ROS was measured under a
microscope, with green fluorescence indicating the
creation of ROS. Results indicated that 125I seeds
stimulated higher level of ROS in both U87 and U251
cells, as reflected by the intensity of green fluorescence
and the percentage of cells carrying ROS. In addition, flow
cytometry analysis revealed that 125I seeds were more
effective in stimulating ROS generation than X-ray
irradiation at the same doses (Figure 4B). For example, the
percentage of U251 cells carrying ROS increased from
79.3% to 97.1%. Moreover, the mean fluorescence intensity
measured by flow cytometry significantly increased by
1.5-fold in U251 cells and 1.8-fold in U87 cells, com-
pared with the control group. Taken together, these
results suggest that the inhibition of GBM cell growth
and EMT induced by 125I seeds may be associated
with ROS generation.
Increased ROS is also known to produce DNA
double-strand breaks (DSBs) with accumulation of the
known marker γH2AX. ATM and its downstream
kinase Chk1 phosphorylate several targets that regulate
DNA repair, cell-cycle checkpoints, and apoptosis [31,32].
Other studies have implicated ROS in the aggressive
behavior of cancer [33]. Moreover, we have found that
125I seeds can induce ROS production. Therefore, we
Figure 3 Effects of 125I seed irradiation on epithelial–mesenchymal transition (EMT) in glioblastoma multiforme (GBM) cells. (A) The
inhibition of cell invasion was measured by transwell and Boyden chamber assays. The number of U251 (left panel) and U87 (right panel) cells was
counted to calculate the average number of migrated cells. (B) A wound-healing assay of GBM cells was performed followed by irradiation at a dose
of 4 Gy, and the U251 cells were presented. The total distance migrated by wounded cells is expressed as a percentage of the initial distance.
(C) Morphological changes of U251 (upper panel) and U87 (lower panel) cells treated by irradiation. (D) The expressions of ZEB1, Snail, and vimentin in
U251 cells treated with 125I seeds (upper panel) and X-ray (lower panel) were measured by western blotting. (E) ZEB1 of U251 cells were measured by
immunofluorescent assay. Data are presented as mean ± SD (n =3). Bars with different characters are statistically different at the P < 0.05 level.
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cell growth and invasion via a ROS-mediated signaling
pathway. To test this hypothesis, western blotting wasperformed and GSH, which can scavenge ROS, was used.
The results indicated that pretreatment of cells with GSH
obviously decreased DNA damage, G2/M arrest, and
Figure 4 Radioactive 125I seeds suppress epithelial–mesenchymal transition (EMT) in glioblastoma multiforme (GBM) cells via a
reactive oxygen species (ROS)-mediated signaling pathway. (A) The levels of ROS in U251 (left panel) and U87 (right panel) cells were
measured by DCF-DA staining 24 hours after 125I seed and X-ray treatment. The green fluorescence intensity indicates the degree of ROS. (B) The
levels of ROS in 125I seed- and X-ray-treated GBM cells were measured by flow cytometric analysis. The mean fluorescence intensity and the cells of
P2 measured by flow cytometric analysis are presented in. (C) Pretreatment of cells with GSH obviously decreased DNA damage and apoptosis in
U251 cells, reflected by γH2AX, activated ATM, ATR, Chk1, and Cdc2. EMT was also recovered by GSH. (D) The number of cells measured by transwell
(upper panel) and Boyden (lower panel) assay was counted to calculate the average number of migrated cells when GSH was used. Moreover,
colony-formation ability of GBM cells (E) of U251 cells, and DNA distribution (F) of U251 cells inhibited by 125I seeds were blocked by recovery of
the expression levels of ROS. Data are presented as mean ± SD (n =3). Bars with different characters are statistically different at the P < 0.05 level.
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EMT associated proteinrecovered when GSH was applied.
To further test whether EMT and cell growth were inhib-
ited via a ROS-mediated signaling pathway, Invasion and
growth of GBM cells were measured with and without
GSH. The results indicated that pretreatment of cells with
GSH recovered the cell invasion suppressed by 125I seeds
(Figure 4D). The inhibited colony-formation in GBM cells
was also rescued by GSH (Figure 4E). Moreover, when
cells were pretreated with GSH, 125I seed-induced cell
apoptosis, as reflected by sub-G1, decreased from 13.46%
to 1.72%, and the percentage of G2/M cells decreased from
22.85% to 8.23% in U251 (Figure 4F). Taken together, these
results suggest that radioactive 125I seeds suppress cell
migration and cell growth by activating a ROS-mediatedsignaling pathway, and that GSH blocks the 125I seed
irradiation-induced inhibition of cell migration and
cell growth.
Radioactive 125I seeds exhibit greater in vivo anticancer
activity than X-ray
An in vivo experiment was performed to further evaluate
the effect of 125I seed irradiation. This study was performed
according to TPS to ensure consistency with clinical
therapy. As anticipated, both X-ray and 125I seed irradiation
at a cumulative dose of 20 Gy significantly inhibited
xenograft tumor growth in vivo (Figure 5A and B).
Measurement of xenograft tumor volumes showed that
the sizes of tumors deriving from the 125I seed and X-ray
groups were significantly smaller than those from the
Figure 5 125I seed irradiation is associated with greater in vivo anticancer activity than X-ray. (A) Representative images of tumors treated
with 125I seed and X-ray irradiation. (B, C) tumor weight and tumor size were measured after irradiation. Data are presented as mean ± SD (n =3).
Significant differences between the 125I seed and X-ray groups under the same dose are indicated by *P < 0.05 and **P < 0.01. (D, E) Proteins with
the involvement of cell growth and epithelial–mesenchymal transition were further detected by IHC and western blotting.
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compared with X-ray irradiation, 125I seed irradiation
more effectively inhibits tumor growth. Moreover, the
expression of proteins associated with DNA damage,
G2/M, apoptosis and EMT were detected in xenograft
tumors by western blotting and IHC. The in vivo
results indicate that 125I seeds caused up-regulation of
γH2AX and of the phosphorylation levels of ATM
(Ser 1981), ATR (Ser 428), and Cdc2 (Tyr 15), indicating
that 125I seeds are more effective than X-ray in inhibiting
cell growth. Moreover, EMT was inhibited by 125I seeds,
as reflected by decreased vimentin and ZEB1 (Figure 5D
and E). Interestingly, the body weight of the nude mice
exposed to X-ray irradiation decreased more significantly
than that of the 125I irradiation group (data not shown).
Taken together, these findings indicate that exposure
to 125I seed radiation is more effective than X-ray in
inhibiting GBM cell growth and EMT in vivo.
Discussion and conclusions
GBM is the most common primary central nervous
system neoplasm in adults. The annual incidence of
malignant gliomas in Western countries is approximately
5 cases per 100,000 people [1]. Unlike most other tumors,extracranial metastases from GBM are extremely rare [2].
In GBM, standard treatment involves maximal resection
followed by concomitant and adjuvant chemoradiotherapy
with temozolomide. Even with complete resection, tumors
will recur because of the infiltrative and diffuse nature of
GBM and its intrinsic radioresistance [34]. Although the
comprehensive treatment strategy for GBM has continu-
ously progressed over recent decades, patients with GBM
still have an extremely poor prognosis with median
survival of 14.6 months [35]. Thus, the discovery of novel
treatments that can overcome the diffuse nature of GBM
and its intrinsic radioresistance has been an aspiration of
scientists in the fields of oncology. Interestingly, previous
clinical trials have indicated that 125I seeds treatment is an
adjuvant therapy to be effective in recurrent GBM [8,36].
Stereotactic brachytherapy (SBT) with 125I seeds was
confirmed to be an effective and safe treatment for patients
with small unresectable or incompletely resected LGG.
Moreover, it has been confirmed that radioactive 125I seed
inhibited the cell growth, migration, and invasion of NPC
cells [12]. These encouraging results compel us to embark
on testing larger numbers of cancer with this treatment
modality. Thus, the current study was performed to inves-
tigate the biological effects of 125I seeds on GBM. Results
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than X-ray irradiation in inhibiting GBM cell growth.
Moreover, EMT in GBM cells was effectively inhibited by
125I seed irradiation in vitro and in vivo. Further studies
indicated that the anticancer effect of 125I seed irradiation
was achieved via a ROS-mediated signaling pathway.
Previous studies have reported that 125I seed irradiation
is more effective than 60CO-γ ray irradiation in inhibiting
cell growth in PANC-1, PC3 prostate cancer, and
CL187 colonic cells [12,14]. Therefore, we evaluated
the radiosensitivity of GBM cells. The results showed
that GBM cells are more sensitive to 125I seed irradiation
than to X-ray irradiation. Moreover, a significant increase
in the proportion of apoptosis with the involvement
caspase-3 and G2/M arrest was observed after 125I seeds
irradiation. Similarly to our results, a prolonged accumula-
tion in the G2/M phase and inhibited growth after expos-
ure to 125I seed irradiation has been previously described
[12,14]. EMT is a tightly regulated process that occurs
during tumor cell metastasis. Without knowledge of
the underlying mechanisms, a previous study reported
that a sublethal dose of X-ray irradiation promoted
the migration and invasion of glioma cells in the
border area during postoperative radiotherapy [37]. In
contrast, some studies have shown that both proton
and carbon ion irradiation significantly decreased cell
migration and invasion [38,39]. Therefore, in our
study, the effects of 125I seed and X-ray irradiation on
GBM cell migration were measured. Interestingly, we
showed that X-ray irradiation promoted the migration
and invasion of GBM cells, while inhibitory effects were
observed in the 125I seed irradiation group. Consistently,
EMT of NPC cell lines were inhibited by 125I seeds [12].
Currently, Kim et al. found that activation of the Snail
pathway by X-ray was important for radioresistance
primarily via EMT induction [40]. Mahabir et al. also
described that GBM post irradiation undergo EMT and
stemness features throughout the early to late phases by
upregulating Snail [30]. Gomez et al. confirmed that non-
small cell lung cancer cells survived X-ray irradiation
treatment display cancer stem cell and EMT phenotypes,
with enhancement of motility and invasiveness and
elevated resistance to apoptosis [41]. On the basis of
these findings that EMT which can be induced by X-ray
irradiation contributes to radioresistance, though a classic
EMT is not involved in GBMs progression, we indicate
that 125I seeds might be an effective treatment for GBM.
What could be the mechanisms behind the inhibition
of GBM cell growth and invasion induced by 125I seed
irradiation? Previous studies confirmed that 125I seed
irradiation inhibited NPC cell line migration by inactivating
VEGF-A/ERK signaling [11]. Kahlert et al. indicated that
the activity of the canonical WNT/β-catenin signaling path-
way was directly associated with increased motility of theGBM cells [18]. However, decreased WNT signaling
or VEGF-A were not observed in GBM cells treated
with 125I seeds (data not shown). As we all know, the
absorption of ionizing radiation by living cells can act
indirectly through radiolysis of water, thereby generat-
ing ROS that can damage nucleic acids, proteins, and
lipids [21]. ROS play an important role in cancer therapy,
particularly with low-LET irradiation [19,42]. Therefore,
we hypothesized that cell growth and invasion inhibition
were induced by 125I seeds with the involvement of in-
creasing ROS. The results indicated that 125I seed ir-
radiation led to a higher level of ROS than X-ray
under the same doses. Moreover, pretreatment of cells
with GSH rescued the EMT and cell growth sup-
pressed by 125I seeds. Taken together, these results in-
dicate that radioactive 125I seeds inhibit GBM cell
invasion and growth via a ROS signaling pathway,
and that ROS inhibition can block the 125I seed
irradiation-induced inhibition of cell migration and cell
growth. Following this, the anticancer action of 125I seed
and X-ray irradiation in vivo was investigated. As with the
in vitro findings, the results indicate that 125I seeds exhibit
greater anticancer activity than X-ray irradiation in vivo.
Increasing evidence suggests that up-regulated ROS
induced by chemotherapy or radiotherapy is associated
with increased EMT of cancer cells. In our study, however,
the results indicate that ROS generated by 125I seeds can
prevent GBM cells migration. This may be due to the type
of ROS, and the dose of irradiation. Luanpitpong et al.
have confirmed that superoxide anions and hydrogen
peroxide down-regulate Cav-1 expression and inhibit
cell migration and invasion, whereas hydroxyl radicals
up-regulate Cav-1 expression and promote cell migration
and invasion [33]. Interestingly, Cav-1 was confirmed to
be down-regulated by 125I seeds in our study, and the
inhibited EMT could be reversed by scavenger of ROS by
GSH. Moreover, Urbich et al. have indicated that CD40
ligand inhibits endothelial cell migration by increasing the
production of endothelial ROS, and that H2O2-prevented
endothelial cell migration can be reversed vitamin C [43].
Although further studies need to perform to confirm the
type of ROS generated by 125I seeds, we can conclude
that 125I seeds can inhibit EMT and growth GBM
cells through increased ROS. Effective treatment options
are limited for patients with GBM, especially for recurrent
GBM, thus, novel treatment approaches are needed. 125I
seeds treatment is an adjuvant therapy that has been
shown to be effective in recurrent GBM [7,44]. Permanent
placement of 125I seeds for recurrent GBM may pro-
long survival in patients with recurrent GBM [36].
Darakchiev et al. have indicated that the use of adjuvant
therapy combining carmustine wafers and permanent 125I
seeds was a good treatment option for patients with recur-
rent GBM who have undergone previous surgery and
Scheme 1 Proposed signaling pathway by which radioactive 125I seeds inhibit epithelial–mesenchymal transition (EMT) and cell
growth in glioblastoma multiforme (GBM) cells. 125I seeds act indirectly through radiolysis of water, thereby generating ROS and producing
DNA damage. DNA damage activates the sensory ATM/ATR kinases and finally results in cell growth inhibition and G2/M arrest. Moreover, ROS
induced by 125I seeds can inhibit EMT via Cav-1 in GBM cells.
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confirmed that 125I was an effective treatment for patients
with GBM. However, our study was performed to investi-
gate the biological effects of 125I seeds on GBM. Our re-
sults indicated that 125I seed irradiation was more effective
than X-ray irradiation in inhibiting GBM cells via the ROS
pathway. Obviously, our data are in line with the majority
of published clinical trials studies. These results reported
here also confirm and extend previous findings. Though
GBM cell growth and invasion were inhibited by radio-
active 125I seeds in this study, however the signaling path-
way via which radioactive 125I seeds inhibited GBM cell
growth and EMT in human GBM was ROS, which was
different from previous study [11].
In summary, we have demonstrated, for the first time,
that radioactive 125I seeds are more effective than X-ray
irradiation in inhibiting GBM cell growth. Moreover,
EMT of GBM cells was effectively inhibited by 125I seed
irradiation. A mechanism study indicated that the cell
growth and EMT inhibition in GBM cells was induced by
125I seeds with the involvement of a ROS signaling path-
way. To our knowledge, this is the first attempt to study
the effect of 125I seeds on GBM cells. These results suggest
that radioactive 125I seeds exhibit novel anticancer activity
via a ROS signaling pathway (Scheme 1). Furthermore,
EMT of GBMs was inhibited by 125I seeds via ROSpathway. These findings have clinical implications for the
treatment of GBM patients with 125I seeds. Based on the
current report, 125I seeds either alone or in combination
with other treatment may be a better choice for GBM
patients. Future studies are needed to determine whether
the biological effects of 125I seed irradiation identified in
GBM cells can be reproduced in other cancer-cell types,
thus broadening the significance of the data reported here.
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